1. De Backer O, Bieliauskas G, Søndergaard L. Current status and future perspectives for transcatheter and surgical aortic valve replacement: the role of aortic valve surgery in the era of transcatheter-based therapies. EuroIntervention. 2018;14(9):e965-7. https://doi.org/10.4244/EIJV14I9A172 https://pubmed.ncbi.nlm.nih.gov/30307396 
2. Deutsch MA, Scotten LN, Siegel R, Lange R, Bleiziffer S. Leaflet thrombosis and clinical events after TAVR: are paravalvular leaks a crucial trigger? EuroIntervention. 2018;14(6):716-7. https://doi.org/10.4244/EIJ-D-18-00348L https://pubmed.ncbi.nlm.nih.gov/30122662 
3. Rashid HN, Cameron JD, Brown AJ. Activation of the coagulation cascade and the role of paravalvular leak in the development of leaflet thrombosis following transcatheter aortic valve replacement. EuroIntervention. 2018;14(6):718-9. https://doi.org/10.4244/EIJ-D-18-00348R https://pubmed.ncbi.nlm.nih.gov/30122663 
4. Vavuranakis M, Kalogeras K, Kolokathis AM, Vrachatis D, Magkoutis N, Siasos G, et al. Antithrombotic therapy in TAVI. J Geriatr Cardiol. 2018;15(1):66-75. https://doi.org/10.11909/j.issn.1671-5411.2018.01.001 https://pubmed.ncbi.nlm.nih.gov/29434628 
5. Mylotte D, Andalib A, Thériault-Lauzier P, Dorfmeister M, Girgis M, Alharbi W, et al. Transcatheter heart valve failure: a systematic review. Eur Heart J. 2015;36(21):1306-27. https://doi.org/10.1093/eurheartj/ehu388 https://pubmed.ncbi.nlm.nih.gov/25265974 
6. Ruparelia N. Oral Anticoagulant Therapy for Early Post-TAVI Thrombosis. Interv Cardiol. 2018;13(1):33-6. https://pubmed.ncbi.nlm.nih.gov/29593834 https://doi.org/10.15420/icr.2017:24:2 
7. Testa L, Latib A. Assessing the Risk of Leaflet Motion Abnormality Following Transcatheter Aortic Valve Implantation. Interv Cardiol. 2018;13(1):37-9. https://pubmed.ncbi.nlm.nih.gov/29593835 https://doi.org/10.15420/icr.2017:24:2 
